Skip to Main Content

Advertisement

Skip Nav Destination

OnlineFirst

Research Article May 24 2022
Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study
Clin Cancer Res clincanres.3867.2021.
Article Commentary May 24 2022
Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases
Clin Cancer Res clincanres.1137.2022.
Research Article May 24 2022
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Clin Cancer Res (2022)
Research Article May 23 2022
CUB domain containing protein 1 (CDCP1) is a target for radioligand therapy in castration resistant prostate cancer including PSMA null disease
Clin Cancer Res clincanres.3858.2021-11-1 14:03:07.837.
Research Article May 23 2022
All About That Ras: Novel Fusion Drives Ras Pathway Activation in Lung Cancer
Clin Cancer Res (2022)
Review Article May 23 2022
Data-Rich Spatial Profiling of Cancer Tissue: Astronomy Informs Pathology
Clin Cancer Res (2022)
Research Article May 20 2022
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancer With MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
Clin Cancer Res clincanres.0437.2022-2-9 05:28:38.980.
Research Article May 20 2022
Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib and venetoclax
Clin Cancer Res clincanres.0433.2022-2-8 15:40:23.327.
Review Article May 20 2022
Cancer Immunoediting in the Era of Immuno-oncology
Clin Cancer Res clincanres.1804.2022.
Research Article May 20 2022
Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma
Clin Cancer Res (2022)
Research Article May 20 2022
Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study
Clin Cancer Res (2022)
Research Article May 20 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Clin Cancer Res (2022)
Article Commentary May 19 2022
War Against NRAS-mutant Melanoma Using Targeted Therapies Remains Challenging
Clin Cancer Res clincanres.1256.2022.
Article Commentary May 19 2022
Hostile Takeover: Tregs expand in IFN-γ-rich AML microenvironment
Clin Cancer Res clincanres.1030.2022.
Research Article May 18 2022
Multiphoton phosphorescence quenching microscopy reveals kinetics of tumor oxygenation during anti-angiogenesis and angiotensin signaling inhibition
Clin Cancer Res clincanres.0486.2022.
Research Article May 18 2022
VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results
Clin Cancer Res clincanres.3811.2021.
Research Article May 18 2022
Phase II clinical trial of Eribulin-gemcitabine combination therapy in previously treated patients with advanced liposarcoma or leiomyosarcoma
Clin Cancer Res clincanres.CCR-22-0518-E.2022.
Research Article May 18 2022
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients
Clin Cancer Res clincanres.0164.2022.
Research Article May 18 2022
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Antagonist, with Nab-Paclitaxel in Solid Tumors
Clin Cancer Res clincanres.4363.2021.
Research Article May 18 2022
Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Clin Cancer Res clincanres.3347.2021.
Review Article May 18 2022
RNA in cancer immunotherapy: unlocking the potential of the immune system
Clin Cancer Res clincanres.3304.2022.
Review Article May 17 2022
Molecular Pathways and Mechanisms of LAG-3 in Cancer Therapy
Clin Cancer Res clincanres.2390.2022.
Research Article May 17 2022
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clin Cancer Res (2022)
Research Article May 17 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Clin Cancer Res (2022)
Research Article May 17 2022
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Clin Cancer Res (2022)
Research Article May 17 2022
The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras–MAPK Signaling in Epithelioid Hemangioendothelioma
Clin Cancer Res (2022)
Research Article May 17 2022
Double Trouble: Whole-Genome Doubling Distinguishes Early from Late Ovarian Cancer
Clin Cancer Res (2022)
Research Article May 16 2022
Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among patients treated for HPV-driven Oropharyngeal Carcinoma
Clin Cancer Res clincanres.0562.2022.
Research Article May 16 2022
Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial
Clin Cancer Res clincanres.0061.2022.
Article Commentary May 16 2022
PD-1 inhibition - trouble for subsequent TIL therapy in patients with melanoma?
Clin Cancer Res clincanres.0832.2022.
Research Article May 12 2022
Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study
Clin Cancer Res clincanres.0305.2022.
Research Article May 12 2022
Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma
Clin Cancer Res clincanres.0171.2022.
Research Article May 12 2022
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer
Clin Cancer Res clincanres.4289.2021.
Research Article May 12 2022
Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer
Clin Cancer Res clincanres.3078.2021.
Research Article May 12 2022
Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma
Clin Cancer Res clincanres.2563.2021.
Research Article May 12 2022
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Clin Cancer Res clincanres.0413.2022.
Research Article May 12 2022
Prostate Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
Clin Cancer Res clincanres.4531.2021.
Review Article May 12 2022
A road map for designing phase I clinical trials of radiotherapy-novel agent combinations
Clin Cancer Res clincanres.4087.2021.
Research Article May 12 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Clin Cancer Res (2022)
Research Article May 12 2022
Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection
Clin Cancer Res (2022)
Review Article May 12 2022
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Clin Cancer Res (2022)
Research Article May 12 2022
Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
Clin Cancer Res (2022)
Research Article May 12 2022
Biomarker Development: Bedside to Bench
Clin Cancer Res (2022)
Research Article May 10 2022
An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors
Clin Cancer Res clincanres.4413.2021.
Research Article May 9 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Clin Cancer Res (2022)
Research Article May 9 2022
Linking Genotype to Phenotype: Bench to Bedside
Clin Cancer Res (2022)
Review Article May 9 2022
Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
Clin Cancer Res (2022)
Research Article May 6 2022
MGP Panel is a comprehensive targeted genomics panel for molecular profiling of multiple myeloma patients
Clin Cancer Res clincanres.3695.2021.
Research Article May 6 2022
MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma
Clin Cancer Res (2022)
Review Article May 6 2022
The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents
Clin Cancer Res (2022)
Page 1 of 3
Close Modal

or Create an Account

Close Modal
Close Modal